Harvoni

New analysis boosts cost-effectiveness argument for Merck's Zepatier
BioPharma Dive
Wed, 04/20/16 - 06:37 pm
Merck
Zepatier
hepatitis C
Harvoni
Gilead Sciences
Merck's 'no patient left behind' approach to hepatitis C
BioPharma Dive
Mon, 04/18/16 - 09:00 pm
Merck
hepatitis C
Zepatier
Gilead Sciences
Sovaldi
Harvoni
Gilead Sciences: ‘Another Pretender to Hepatitis C Throne Seems to Be Suffering the AbbVie Fate’
Barron's
Mon, 03/28/16 - 11:32 am
Gilead Sciences
hepatitis C
Merck
Zepatier
Harvoni
Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny
Motley Fool
Sat, 03/26/16 - 01:04 pm
Merck
Gilead Sciences
Ionis Pharmaceuticals
hepatitis C
patents
Harvoni
Sovaldi
Gilead to Pay Merck $200 Million in Damages Over Hepatitis C Drug Patents
WSJ Online
Fri, 03/25/16 - 09:42 am
Gilead Sciences
Harvoni
Sovaldi
hepatitis C
Merck
Patent Troubles Hit Biogen After Gilead, Regeneron; What’s Next?
Bidness, ETC
Fri, 03/25/16 - 09:39 am
Biogen
Gilead
Regeneron
patents
Tecfidera
Harvoni
Sovaldi
Gilead has taken a lot of hits lately. Here’s what it really has to fear
Stat
Thu, 03/24/16 - 04:35 pm
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Gilead's CEO: We are appealing the case
CNBC
Thu, 03/24/16 - 09:29 am
Gilead Sciences
patents
Merck
John Milligan
Harvoni
Sovaldi
hepatitis C
Gilead May Have to Pay Rival Merck Billions in Royalties
Fortune
Wed, 03/23/16 - 04:04 pm
Gilead Sciences
Merck
patents
sofosbuvir
Harvoni
Sovaldi
hepatitis C
Merck wins major victory in hep C patent case against Gilead
BioPharma Dive
Wed, 03/23/16 - 09:45 am
Merck
hepatitis C
patents
Gilead Sciences
sofosbuvir
Harvoni
Sovaldi
Gilead And The $3 Billion Merck Issue
Seeking Alpha
Fri, 03/18/16 - 11:10 am
Gilead Sciences
Merck
patents
hepatitis C
Harvoni
Sovaldi
Gilead (GILD) Stock Gains, Owns 94% of Hepatitis-C Market
TheStreet.com
Sat, 03/12/16 - 09:39 am
Gilead Sciences
Harvoni
Sovaldi
hepatitis C
Inside the $100 million ad blitz for a $1,100-a-pill drug for hepatitis C
Stat
Wed, 03/9/16 - 10:31 am
hepatitis C
drug ads
Harvoni
Gilead Sciences
Gilead, Merck Spar Over Hepatitis C $1,000-Pill Royalties
Bloomberg
Mon, 03/7/16 - 09:58 pm
Gilead Sciences
Merck
hepatitis C
Sovaldi
Harvoni
Gilead's 3 Most Profitable Lines of Business
Investopedia
Mon, 03/7/16 - 09:44 am
Gilead Sciences
Truvada
Sovaldi
Harvoni
hepatitis C
hepatitis B
HIV
Gilead: Hep C Prescriptions Hold at 94% Among New Patients
Barron's
Fri, 03/4/16 - 02:48 pm
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Will Merck Encroach On Gilead's Harvoni Territory?
Yahoo/Benzinga
Tue, 02/23/16 - 05:44 pm
Merck
Gilead
Harvoni
AbbVie
hepatitis C
Viekira Pak
Zepatier
Should Gilead Investors Fear Regulus?
Seeking Alpha
Thu, 02/18/16 - 09:37 am
Gilead Sciences
Regulus
hepatitis C
Harvoni
RG-101
Harvoni’s New Label Gives Gilead Edge Over AbbVie
Bidness, ETC
Wed, 02/17/16 - 10:42 am
Harvoni
labeling
Gilead Sciences
AbbVie
Viekira Pak
hepatitis C
FDA expands use of Gilead's liver drug to rare subset of patients
Yahoo/Reuters
Tue, 02/16/16 - 10:28 am
FDA
Gilead Sciences
Harvoni

Pages